A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 53-60

  Gaztanaga, Juan ^a   Farkouh, Michael ^b,c   Rudd, James H F ^d   Brotz, Tilmann M ^e,j   Rosenbaum, David ^f   Mani, Venkatesh ^b   Kerwin, Todd C ^g   Taub, Rebecca ^e   Tardif, Jean Claude ^h   Tawakol, Ahmed ⁱ   Fayad, Zahi A ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e VIA Pharmaceuticals Inc ^*  (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g NEW YORK HOSPITAL QUEENS   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Konzept Drug Development Consulting   (United States)

more..

Author keywords

18Fluorodeoxyglucose positron emission tomography; Acute coronary syndrome; Arachidonate 5 lipoxygenase inhibitor; Inflammation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; LEUKOTRIENE B4; PLACEBO; HYDROXYUREA; LIPOXYGENASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ARTERIAL INFLAMMATION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PET SCANNER; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULITIS; AGED; ANALOGS AND DERIVATIVES; AORTITIS; AORTOGRAPHY; CANADA; CAROTID ARTERY DISEASES; CLINICAL TRIAL; ENZYMOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODAL IMAGING; PREDICTIVE VALUE; PROCEDURES; TIME; UNITED STATES;

ACUTE CORONARY SYNDROME; AGED; AORTITIS; AORTOGRAPHY; CANADA; CAROTID ARTERY DISEASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULITIS;

EID: 84925939829     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.027     Document Type: Article

References (44)

1. Ross R. Atherosclerosis-an inflammatory disease. N.Engl. J. Med. 1999, 340(2):115-126.
2. Llodra J., Angeli V., Liu J., Trogan E., Fisher E.A., Randolph G.J. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(32):11779-11784. PMCID: 511052.
3. Faxon D.P., Fuster V., Libby P., Beckman J.A., Hiatt W.R., Thompson R.W., et al. Atherosclerotic vascular disease conference: writing group III: pathophysiology. Circulation 2004, 109(21):2617-2625.
4. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 2004, 116(Suppl.6A):9S-16S.
5. Youn C.S., Choi S.P., Kim S.H., Oh S.H., Jeong W.J., Kim H.J., et al. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am. J. Emerg. Med. 2012, 30(1):124-128.
6. Goldstein J.A., Demetriou D., Grines C.L., Pica M., Shoukfeh M., O'Neill W.W. Multiple complex coronary plaques in patients with acute myocardial infarction. N.Engl. J. Med. 2000, 343(13):915-922.
7. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N.Engl. J. Med. 2002, 347(1):5-12.
8. Spagnoli L.G., Bonanno E., Mauriello A., Palmieri G., Partenzi A., Sangiorgi G., et al. Multicentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarction. J.Am. Coll. Cardiol. 2002, 40(9):1579-1588.
9. Rioufol G., Finet G., Ginon I., Andre-Fouet X., Rossi R., Vialle E., et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002, 106(7):804-808.
10. Dutta P., Courties G., Wei Y., Leuschner F., Gorbatov R., Robbins C.S., et al. Myocardial infarction accelerates atherosclerosis. Nature 2012, 487(7407):325-329. PMCID: 3401326.
11. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97(20):2007-2011.
12. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet 1997, 349(9050):462-466.
13. Liuzzo G., Biasucci L.M., Gallimore J.R., Grillo R.L., Rebuzzi A.G., Pepys M.B., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N.Engl. J. Med. 1994, 331(7):417-424.
14. Heeschen C., Hamm C.W., Bruemmer J., Simoons M.L. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet therapy in unstable angina refractory to standard treatment trial. J.Am. Coll. Cardiol. 2000, 35(6):1535-1542.
15. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103(7):926-933.
16. Takeda T., Hoshida S., Nishino M., Tanouchi J., Otsu K., Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003, 169(1):155-158.
17. Mizoguchi M., Tahara N., Tahara A., Nitta Y., Kodama N., Oba T., et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc. imaging 2011, 4(10):1110-1118.
18. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285(13):1711-1718.
19. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983, 220(4597):568-575.
20. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237(4819):1171-1176.
21. Wong S.L., Drajesk J., Chang M., Lanni C., Witt G., Hansen R., et al. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. Clin. Pharmacol. Ther. 1998, 63(3):324-331.
22. Hansson A., Tabibiazar R., Wohlgemuth J., Sanan D., Quartermous T. Abstract: attenuation of atherosclerosis and monocyte-macrophage inflammation in ApoE-deficient mice treated with the 5-lipoxygenase inhibitor VIA-2291. Circulation 2007, 116. II_209.
23. Tardif J.C., L'Allier P.L., Ibrahim R., Gregoire J.C., Nozza A., Cossette M., et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ. Cardiovasc. Imaging 2010, 3(3):298-307.
24. Rudd J.H., Warburton E.A., Fryer T.D., Jones H.A., Clark J.C., Antoun N., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105(23):2708-2711.
25. Tawakol A., Migrino R.Q., Bashian G.G., Bedri S., Vermylen D., Cury R.C., et al. Invivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J.Am. Coll. Cardiol. 2006, 48(9):1818-1824.
26. Fayad Z.A., Mani V., Woodward M., Kallend D., Abt M., Burgess T., et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011, 378(9802):1547-1559.
27. Rudd J.H., Myers K.S., Bansilal S., Machac J., Rafique A., Farkouh M., et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J.Am. Coll. Cardiol. 2007, 50(9):892-896.
28. Tawakol A., Fayad Z.A., Mogg R., Alon A., Klimas M.T., Dansky H., et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J.Am. Coll. Cardiol. 2013, 62(10):909-917.
29. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N.Engl. J. Med. 2004, 350(1):29-37.
30. Drazen J.M., Yandava C.N., Dube L., Szczerback N., Hippensteel R., Pillari A., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 1999, 22(2):168-170.
31. Afilalo J., Majdan A.A., Eisenberg M.J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007, 93(8):914-921. PMCID: 1994400.
32. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American college of cardiology/American heart association task force on practice guidelines (Writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine. J.Am. Coll. Cardiol. 2007, 50(7):e1-e157.
33. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N.Engl. J. Med. 2004, 350(15):1495-1504.
34. Wu Y.W., Kao H.L., Huang C.L., Chen M.F., Lin L.Y., Wang Y.C., et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur. J. Nucl. Med. Mol. Imaging March 2012, 39(3):399-407.
35. Tahara N., Kai H., Ishibashi M., Nakaura H., Kaida H., Baba K., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J.Am. Coll. Cardiol. 2006, 48(9):1825-1831.
36. Tawakol A., Fayad Z.A., Mogg R., Alon A., Subramanian S., Abdelbaky A., et al. High dose statin results in a further reduction in atherosclerotic inflammation comapred with low dose statin: results of a Multi-Center PET-CT study. Circulation 2011, 124.
37. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N.Engl. J. Med. 2008, 359(21):2195-2207.
38. Kinlay S., Schwartz G.G., Olsson A.G., Rifai N., Leslie S.J., Sasiela W.J., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108(13):1560-1566.
39. Gomez-Hernandez A., Sanchez-Galan E., Ortego M., Martin-Ventura J.L., Blanco-Colio L.M., Tarin-Vicente N., et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome. Am. J. Cardiol. 2008, 102(1):12-18.
40. Tu X.K., Yang W.Z., Shi S.S., Chen C.M., Wang C.H. 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol. Res. 2009, 31(8):848-852.
41. Rossi A., Pergola C., Koeberle A., Hoffmann M., Dehm F., Bramanti P., et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br. J. Pharmacol. 2010, 161(3):555-570. PMCID: 2990155.
42. Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 2006, 5(11):2716-2726.
43. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N.Engl. J. Med. 2009, 361(11):1045-1057.
44. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N.Engl. J. Med. 2005, 352(1):20-28.